Press release
GervanoRA Announced the Release of Opportunity Assessment Report Titled “Spinal Cord Injury Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018”
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Spinal Cord Injury Pipeline Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics, and Pipeline Analysis H2 2018.GervanoRA’s pipeline analysis and opportunity assessment report “Spinal Cord Injury: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2018” analyzed and assessed Spinal Cord Injury pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Spinal Cord Injury industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Unmet needs and Opportunities
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Patent Analysis of Pipeline Molecules
• Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. REPORT MAJOR FINDINGS
2.2. KEY EVENTS IN SPINAL CORD INJURY COMPETITIVE SPACE
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET DYNAMICS
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EX-US) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. SPINAL CORD INJURY PHASE 3 MOLECULES
5.1.2. SPINAL CORD INJURY PHASE 2 MOLECULES
5.1.3. SPINAL CORD INJURY PHASE 1 MOLECULES
5.1.4. SPINAL CORD INJURY PRECLINICAL MOLECULES
5.1.5. SPINAL CORD INJURY EARLY R&D MOLECULES
5.1.6. SPINAL CORD INJURY INACTIVE AND DISCONTINUED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6. PIPELINE MOLECULES BY UNIVERSITIES AND INSTITUTES
6 ESTIMATED APPROVAL TIMELINE
6.1.1. METHODOLOGY
6.1.2. ESTIMATED APPROVAL TIME LINES US & EX-US
7. SPINAL CORD INJURY CLINICAL TRIALS SUMMARY
7.1. SPINAL CORD INJURY PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
7.1.1. KEY PHASE 3 RESULTS
7.1.2. KEY PHASE 2 RESULTS
7.2. ONGOING CLINICAL TRIALS SUMMARY
7.2.1 KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
7.2.2 KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
7.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
7.3. PLANNED CLINICAL TRIALS SUMMARY
7.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
7.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
7.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
7.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
8. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
8.1. COMPANIES
8.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
8.1.2. TOP 20 EMERGING COMPANIES IN THE SPINAL CORD INJURY AREA
8.3. UNIVERSITIES AND INSTITUTES – LICENSING OPPORTUNITIES
9. ABBREVIATIONS
LIST OF TABLES:
TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 02: DISEASE EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
TABLE 03: MAJOR COLLABORATIVE AGREEMENTS IN THE SPINAL CORD INJURY AREA
TABLE 04: MAJOR LICENSING AGREEMENTS IN THE SPINAL CORD INJURY AREA
TABLE 05: MAJOR MERGERS AND ACQUISITIONS IN THE SPINAL CORD INJURY AREA
TABLE 06: MAJOR ALLIANCE AGREEMENTS IN THE SPINAL CORD INJURY AREA
TABLE 07: MAJOR FINANCING DEALS IN THE SPINAL CORD INJURY AREA
TABLE 08: MAJOR DEALS IN THE SPINAL CORD INJURY AREA RANKED BY DEAL AMOUNT
TABLE 09: US FDA APPROVED DRUGS SINCE 2010
TABLE 10: EX-US APPROVED DRUGS SINCE 2010
TABLE 11: PHASE 3 MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 12: PHASE 2 MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 13: PHASE 1 MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 14: PRECLINICAL MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 15: EARLY R&D MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 16: INACTIVE AND DISCONTINUED MOLECULES IN THE SPINAL CORD INJURY DRUG PIPELINE
TABLE 17: SPINAL CORD INJURY PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 18: SPINAL CORD INJURY PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 19: SPINAL CORD INJURY PIPELINE MOLECULES BY UNIVERSITIES
TABLE 20: SPINAL CORD INJURY PIPELINE MOLECULES BY INSTITUTES
TABLE 21: ESTIMATED APPROVAL Time lines OF PIPELINE MOLECULES
TABLE 22: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 23: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 24: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 25: PLANNED CLINICAL TRIALS FOR THE SPINAL CORD INJURY AREA
TABLE 26: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 27: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 28: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 29: ESTABLISHED COMPANIES SCENARIO
TABLE 30: LIST OF EMERGING COMPANIES IN THE SPINAL CORD INJURY AREA
TABLE 31: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 32: COMPETITIVE OPPORTUNITIES, INSTITUTES
(Above mentioned tables are a few among the total 95 tables in the report)
LIST OF FIGURES:
FIGURE 01: KEY PIPELINE EVENTS, 2019-2029
FIGURE 02: SPINAL CORD INJURY EPIDEMIOLOGY (2017), FORECAST (2018-2025) IN MILLIONS
FIGURE 03: OVERALL DEALS ACTIVITY IN THE SPINAL CORD INJURY AREA
FIGURE 04: OVERALL DEAL FINANCING ACTIVITY V/S DEAL TYPE
FIGURE 05: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 06: SPINAL CORD INJURY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 07: SPINAL CORD INJURY DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 08: SPINAL CORD INJURY DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 09: SPINAL CORD INJURY DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 10: SPINAL CORD INJURY DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 11: SPINAL CORD INJURY PIPELINE MOLECULES DEVELOPED BY UNIVERSITIES AND INSTITUTES
FIGURE 12: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 13: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 14: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 15: COMPANY FINANCIAL INFORMATION
FIGURE 16: COMPANY SWOT ANALYSIS
(Above mentioned figures are a few among the total 50 figures in the report)
This report is available on promotional basis.
To view sample report: www.gervanora.com/request-for-sample-report/
Why Choose GervanoRA??
GervanoRA is working dedicatedly for healthcare (Pharma & Medical Device) domain to empower our client’s business by assisting them in decision making with our wealthiness of database, expertise in analytics, and domain experts.
Vast & Tailor-made Database: GervanoRA utilizes its in-built rich database of pharmaceutical sector and Medical device sector to help our clients with their bespoke requirements. We have databases of Pharma Pipeline Drugs, Pharma News, Pharma Deals and Pipeline Medical Devices, Medical Device News and Medical Device Deal.
Coverage: We cover almost all major countries on the globe by providing Pharma & Medical device pipeline insights along with epidemiology, epidemiology forecast, Patent analysis, Insights on clinical trials and emerging opportunities. Using our database analytics, we are cracking the future numbers to assess market opportunities in healthcare domain.
Resources to meet the Goals: We have great number of experts, Analysts, Senior Researchers and Researchers to take care of our dynamic day to day process, like building database, updating the database, optimizing primary inputs, using internal tools analytics, Conducting KOL Interviews and Gathering field intelligence through paid surveys in all healthcare markets.
About GervanoRA:
GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we are playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.
To assist our global clients to attain their segment and sub segment specific goals, we are enlightening them on domain specific live updates through our GervanoRA 360 Degree PharmMedTech Monthly Bulletin (Monthly Report) which serve our clients with bespoke requirements without missing any live update for the particular month, as we know how valuable it is to be stayed updated with day to day dynamic industry sectors.
GervanoRA Data Services LLP
Goa IT Innovation Centre,
Goa Chamber of Commerce and Industry Bldg, 2nd Floor, S-2 Block,
Opp: Hyundai Showroom, Verna, South Goa,
Goa INDIA 403722
Email: sales@gervanora.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GervanoRA Announced the Release of Opportunity Assessment Report Titled “Spinal Cord Injury Drugs – Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2018” here
News-ID: 1732799 • Views: …
More Releases from GervanoRA Data Services
GervanoRA Announces Financial Results of 2022-2023
GervanoRA Data Services (GDS) is an AI based emerging healthcare consulting company based in Goa India with 12 global offices spread across the world, announced today that it has released the financial results of 2022-2023 and with our tremendous team efforts, we achieved around 18% growth in earnings, 28% increments in developmental activities and 30% growth in monetary hold compared to the previous financial year 2021-2022. We are providing AI…

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Hemophilia A - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report.
GervanoRA’s pipeline analysis and opportunity assessment report “Hemophilia A: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Hemophilia A pipeline molecules for the opportunities in the…

GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Schizophrenia - Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis H2 2019 Report.
GervanoRA’s pipeline analysis and opportunity assessment report “Schizophrenia: Opportunity Assessments, Epidemiology, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Schizophrenia pipeline molecules for the opportunities in the competitive space by…
GervanoRA Announced the Release of Market Dynamics and Opportunity Assessment Re …
GervanoRA Data Services (GDS), a premier provider of market research analysis and services based in Goa, India has announced the release of their latest report on Beta-Thalassemia Pipeline Drugs - Pipeline Analysis, Opportunity Assessments, Epidemiology Forecast, Market Dynamics, H2 2019 .
GervanoRA’s pipeline analysis and opportunity assessment report “Beta-Thalassemia: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis, H2 2019” analyzed and assessed Beta-Thalassemia pipeline molecules for the opportunities in the…
More Releases for SPINAL
Evolving Market Trends In The Spinal Fusion Devices Industry: Advancements In Sp …
The Spinal Fusion Devices Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]._x000D_
_x000D_
What Is the Expected Spinal Fusion Devices Market Size During the Forecast Period?_x000D_
Over the past few years, there has been a significant growth in the spinal fusion devices market. The market is projected…
Key Influencer in the Spinal Fusion Devices Market 2025: Rising Spinal Disorder …
What Is the Forecasted Market Size and Growth Rate for the Spinal Fusion Devices Market?
The market for spinal fusion devices has experienced significant growth in the past couple of years. Expectations are that it will rise from estimates of $7.85 billion in 2024 to approximately $8.31 billion in 2025, giving us a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this notable expansion during the historical period can…
Disposable Spinal Instrument Market: Revolutionizing Spinal Surgery with Hygiene …
Introduction
The medical device market has witnessed a surge in demand for disposable instruments, especially in areas where hygiene, precision, and efficiency are paramount. One such sector experiencing rapid growth is the disposable spinal instrument market. Spinal surgeries, being intricate and requiring high precision, have traditionally relied on reusable instruments. However, growing concerns about hygiene, infection control, and surgical efficiency have accelerated the shift toward disposable spinal instruments. These devices not…
Endoscopic Spinal Surgery Market: Minimally Invasive Solutions for Spinal Disord …
Global Endoscopic Spinal Surgery Market size was valued at US$ 667 Mn. in 2022 and the total revenue is expected to grow at a CAGR of 7.9% through 2022 to 2029, reaching nearly US$ 1137 Mn.
Endoscopic Spinal Surgery Market Overview:
Maximize Market Research is a research firm that has published a detailed analysis of the "Endoscopic Spinal Surgery Market". MMR in-depth market assessments in research reports consider significant technological advancements in…
Spinal Resilience: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
Market Outlook:
Charting Progress: Acute Spinal Cord Injury Drug Pipeline Landscape (2023)
The Acute Spinal Cord Injury Drug Pipeline Landscape sets its sights on a decade of advancements poised to redefine the trajectory of spinal resilience. This comprehensive outlook explores the unfolding strategies, innovations, and breakthroughs that promise to revolutionize the landscape of acute spinal cord injury treatment.
Market Drivers:
Neuroregeneration on the Horizon: At the forefront of the Acute Spinal Cord Injury Drug…
Spinal Laminoplasty Market - Revolutionizing spinal care with minimally invasive …
Newark, New Castle, USA: The "Spinal Laminoplasty Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Spinal Laminoplasty Market: https://www.growthplusreports.com/report/spinal-laminoplasty-market/8601
This latest report researches the industry structure, sales, revenue,…